Trevi Therapeutics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Trevi Therapeutics, Inc. (TRVI) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $207.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-06
- Trevi Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $102.00K, a 7.27% decline year-over-year.
- Trevi Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $105.00K, a 6.25% decline year-over-year.
- Trevi Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $107.00K, a 45.96% decline year-over-year.
- Trevi Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $108.00K, a 272.41% increase year-over-year.
- Trevi Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $437.00K, a 5.00% decline from fiscal 2024.
- Trevi Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $460.00K, a 22.02% increase from fiscal 2023.
- Trevi Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $377.00K.
- Trevi Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $0.00.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $102.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $207.00K 10-Q · filed 2026-08-06 | $314.00K derived: sum of 3 quarters · filed 2026-08-06 | $422.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $105.00K 10-Q · filed 2026-05-05 | $212.00K derived: sum of 2 quarters · filed 2026-05-05 | $320.00K derived: sum of 3 quarters · filed 2026-05-05 | $430.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $107.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $215.00K derived: sum of 2 quarters · filed 2026-03-17 | $325.00K derived: sum of 3 quarters · filed 2026-08-06 | $437.00K 10-K · filed 2026-03-17 |
| 2025-09-30 | $108.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $218.00K derived: sum of 2 quarters · filed 2026-08-06 | $330.00K 10-Q · filed 2025-11-13 | $528.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $110.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $222.00K 10-Q · filed 2026-08-06 | $420.00K derived: sum of 3 quarters · filed 2026-08-06 | $449.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $112.00K 10-Q · filed 2026-05-05 | $310.00K derived: sum of 2 quarters · filed 2026-05-05 | $339.00K derived: sum of 3 quarters · filed 2026-05-05 | $452.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $198.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $227.00K derived: sum of 2 quarters · filed 2026-03-17 | $340.00K derived: sum of 3 quarters · filed 2026-03-17 | $460.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | $29.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $142.00K derived: sum of 2 quarters · filed 2025-11-13 | $262.00K 10-Q · filed 2025-11-13 | $380.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $113.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $233.00K 10-Q · filed 2025-08-07 | $351.00K derived: sum of 3 quarters · filed 2025-08-07 | $470.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $120.00K 10-Q · filed 2025-05-08 | $238.00K derived: sum of 2 quarters · filed 2025-05-08 | $357.00K derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | $118.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $237.00K derived: sum of 2 quarters · filed 2025-03-18 | $377.00K 10-K · filed 2025-03-18 | |
| 2023-09-30 | $119.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $259.00K 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $140.00K 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | -$100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | -$67.00K derived: sum of 2 quarters · filed 2024-03-20 | $0.00 10-K · filed 2024-03-20 | |
| 2022-09-30 | $33.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $100.00K 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $67.00K 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |